EP 3384926 A1 20181010 - CANCER VACCINE COMPOSITION
Title (en)
CANCER VACCINE COMPOSITION
Title (de)
KREBSIMPFSTOFFZUSAMMENSETZUNG
Title (fr)
COMPOSITION DE VACCIN CONTRE LE CANCER
Publication
Application
Priority
- JP 2007314552 A 20071205
- EP 08857437 A 20081205
- JP 2008072160 W 20081205
Abstract (en)
A cancer vaccine composition for human leukocyte antigen (HLA) -A*0206-positive persons, comprising a protein product of the tumor suppressor gene WT1 or a partial peptide thereof.
IPC 8 full level
A61K 39/00 (2006.01); A61K 35/15 (2015.01); A61K 35/17 (2015.01); A61K 39/39 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01); C07K 7/06 (2006.01); C12N 5/0783 (2010.01); C12N 5/0784 (2010.01); G01N 33/574 (2006.01); C07K 14/47 (2006.01); G01N 33/569 (2006.01)
CPC (source: CN EP KR RU US)
A61K 35/15 (2013.01 - KR US); A61K 35/17 (2013.01 - KR US); A61K 38/08 (2013.01 - KR); A61K 39/0011 (2013.01 - KR); A61K 39/001153 (2018.08 - US); A61K 39/4611 (2023.05 - CN EP RU); A61K 39/4615 (2023.05 - CN EP RU); A61K 39/4622 (2023.05 - CN EP RU); A61K 39/464453 (2023.05 - CN EP RU); A61P 35/00 (2018.01 - EP); A61P 35/02 (2018.01 - EP); A61P 35/04 (2018.01 - KR); A61P 37/04 (2018.01 - EP); C07K 7/06 (2013.01 - CN EP KR RU US); C07K 14/4748 (2013.01 - CN EP KR RU US); C12N 5/0638 (2013.01 - CN EP KR RU US); C12N 5/0639 (2013.01 - CN EP KR RU US); G01N 33/56972 (2013.01 - EP KR US); G01N 33/574 (2013.01 - CN EP US); G01N 33/57496 (2013.01 - KR US); A61K 2039/5154 (2013.01 - KR US); A61K 2039/5158 (2013.01 - KR US); A61K 2039/53 (2013.01 - CN KR US); A61K 2039/54 (2013.01 - KR US); A61K 2039/545 (2013.01 - KR US); A61K 2121/00 (2013.01 - KR); A61K 2239/48 (2023.05 - CN EP RU); C12N 2501/40 (2013.01 - KR US)
Citation (applicant)
- EP 1127068 A1 20010829 - IMP COLLEGE INNOVATIONS LTD [GB]
- JP H09104629 A 19970422 - KISHIMOTO CHUZO, et al
- JP H1135484 A 19990209 - SUGIYAMA HARUO
- WO 0006602 A1 20000210 - SUGIYAMA HARUO [JP], et al
- JP 2006045287 A 20060222
- JP 2006355356 A 20061228
- WO 2005053618 A2 20050616 - SLOAN KETTERING INST CANCER [US]
- WO 2007016466 A2 20070208 - SLOAN KETTERING INST CANCER [US], et al
- GESSLER, M. ET AL., NATURE, vol. 343, 1990, pages 774 - 778
- CUR. OPIN. IMMUNOL., vol. 5, 1993, pages 709
- CUR. OPIN. IMMUNOL., vol. 5, 1993, pages 719
- CELL, vol. 82, 1995, pages 13
- IMMUNOL. REV., vol. 146, 1995, pages 167
- MOL. CELL. BIOL., vol. 11, 1991, pages 1707
- "Peptide Synthesis", 1966, INTERSCIENCE
- "The Proteins", vol. 2, 1976, ACADEMIC PRESS INC.
- "Peptide synthesis", 1975, MARUZEN CO., LTD.
- "Basis and Experiments of Peptide Synthesis", 1985, MARUZEN CO., LTD.
- "Sequel to Development of Pharmaceuticals", vol. 14, 1991, HIROKAWA PUBLISHING COMPANY
- J. IMMUNOLOGICAL METHODS, vol. 181, 1995, pages 45 - 54
Citation (search report)
- [I] EP 1640458 A1 20060329 - SUGIYAMA HARUO [JP]
- [I] EP 1103564 A1 20010530 - SUGIYAMA HARUO [JP]
- [A] TROST BRETT ET AL: "Strength in numbers: achieving greater accuracy in MHC-I binding prediction by combining the results from multiple prediction tools", IMMUNOME RESEARCH, BIOMED CENTRAL, LONDON, GB, vol. 3, no. 1, 24 March 2007 (2007-03-24), pages 5, XP021025750, ISSN: 1745-7580, DOI: 10.1186/1745-7580-3-5
- [XPI] ZHEYU LI ET AL: "Identification of a WT1 protein-derived peptide, WT1 187 , as a HLA-A*0206-restricted, WT1-specific CTL epitope", MICROBIOLOGY AND IMMUNOLOGY, vol. 52, no. 11, 1 November 2008 (2008-11-01), pages 551 - 558, XP055013597, ISSN: 0385-5600, DOI: 10.1111/j.1348-0421.2008.00069.x
- [A] TANIGAKI N ET AL: "HLA-A2-binding peptides cross-react not only within the A2 subgroup but also with other HLA-A-Locus allelic products", HUMAN IMMUNOLOGY, NEW YORK, NY, US, vol. 39, no. 3, 1 March 1994 (1994-03-01), pages 155 - 162, XP023940021, ISSN: 0198-8859, [retrieved on 19940301], DOI: 10.1016/0198-8859(94)90255-0
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR
DOCDB simple family (publication)
EP 2228072 A1 20100915; EP 2228072 A4 20120314; EP 2228072 B1 20180613; AU 2008332278 A1 20090611; AU 2008332278 B2 20130613; AU 2008332278 C1 20131003; CA 2706907 A1 20090611; CA 2706907 C 20161018; CA 2881594 A1 20090611; CA 2881594 C 20160412; CA 2940962 A1 20090611; CA 2940962 C 20180724; CN 101888852 A 20101117; CN 101888852 B 20170208; CN 103394079 A 20131120; CN 103394079 B 20170301; CN 105903006 A 20160831; EP 3384926 A1 20181010; ES 2679127 T3 20180822; JP 2013241417 A 20131205; JP 2016166223 A 20160915; JP 5478260 B2 20140423; JP 5921494 B2 20160524; JP 6435286 B2 20181205; JP WO2009072610 A1 20110428; KR 101592855 B1 20160212; KR 101610664 B1 20160408; KR 20100090710 A 20100816; KR 20150055091 A 20150520; MX 2010006070 A 20101206; RU 2010127298 A 20120110; RU 2013141920 A 20150320; RU 2013141923 A 20150320; RU 2682726 C2 20190322; RU 2682726 C9 20190815; RU 2721574 C2 20200520; TW 200930402 A 20090716; TW 201406390 A 20140216; TW I455721 B 20141011; TW I504407 B 20151021; US 10426822 B2 20191001; US 11707512 B2 20230725; US 2011070251 A1 20110324; US 2014023670 A1 20140123; US 2016367649 A1 20161222; US 2017232089 A1 20170817; US 2019388529 A1 20191226; US 8557779 B2 20131015; US 9119801 B2 20150901; WO 2009072610 A1 20090611
DOCDB simple family (application)
EP 08857437 A 20081205; AU 2008332278 A 20081205; CA 2706907 A 20081205; CA 2881594 A 20081205; CA 2940962 A 20081205; CN 200880119136 A 20081205; CN 201310241647 A 20081205; CN 201610202421 A 20081205; EP 18156472 A 20081205; ES 08857437 T 20081205; JP 2008072160 W 20081205; JP 2009544741 A 20081205; JP 2013131438 A 20130624; JP 2016079557 A 20160412; KR 20107013987 A 20081205; KR 20157011229 A 20081205; MX 2010006070 A 20081205; RU 2010127298 A 20081205; RU 2013141920 A 20130912; RU 2013141923 A 20081205; TW 102139047 A 20081205; TW 97147299 A 20081205; US 201313920757 A 20130618; US 201514631336 A 20150225; US 201615530247 A 20161216; US 201916539613 A 20190813; US 74625708 A 20081205